Adem Yavuz, Suleyman Aydin, Bilgin Gurates

Serum and salivary obestatin concentrations in thediagnosis of polycystic ovary syndrome

Aim: : To measure obestatin levels in the blood and saliva samples of normal-weight patients with polycystic ovary syndrome(PCOS) in comparison with normal-weight healthy controls, and to determine whether there were relationships between blood and/or salivary obestatin levels and other measured parameters.Materials and Methods: Fifteen healthy women and 15 patients with PCOS, all of which had normal weight, were included in thestudy. Participants’ age, height, weight, menstrual characteristics, hormone levels, body mass index, waist/hip ratio, and modified Ferriman-Gallwey (FG) scores were recorded. Obestatin levels were measured in both fasting blood and saliva samples. Homeostasis Model Assessment (HOMA-IR) was used to predict insulin resistance.Results: In the PCOS group, menstrual cycle duration and FG scores were significantly higher (P-value,

PDF

___

1. Bozdag G, Mumusoglu S, Zengin D, et al. The prevalence and phenotypic features of polycystic
ovary syndrome: a systematic review and meta-
analysis. Hum Reprod 2016;31:2841-55.
2. Group REASPCW. Revised 2003 consensus on
diagnostic criteria and long-term health risks related
to polycystic ovary syndrome (PCOS). Human
reproduction 2004;19:41-7.
3. Escobar-Morreale HF. Polycystic ovary syndrome:
definition, aetiology, diagnosis and treatment. Nat Rev
Endocrinol 2018;14:270-84.
4. Rosenfield RL, Ehrmann DA. The Pathogenesis of
Polycystic Ovary Syndrome (PCOS): The Hypothesis
of PCOS as Functional Ovarian Hyperandrogenism
Revisited. Endocr Rev 2016;37:467-520.
5. Zhang JV, Ren PG, Avsian-Kretchmer O, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005;310:996-9.
6. Tang SQ, Jiang QY, Zhang YL, et al. Obestatin: its
physicochemical characteristics and physiological
functions. Peptides 2008;29:639-45.
7. Granata R, Settanni F, Gallo D, et al. Obestatin
promotes survival of pancreatic beta-cells and human
islets and induces expression of genes involved in the
regulation of beta-cell mass and function. Diabetes
2008;57:967-79.
8. Pradhan G, Wu C-S, Lee JH, et al. Obestatin stimulates
glucose-induced insulin secretion through ghrelin
receptor GHS-R. Sci Rep 2017;7:979.
9. Romani F, Lanzone A, Tropea A, et al. In vitro effect of
unacylated ghrelin and obestatin on human luteal cell
function. Fertil Steril 2012;97:991-6.
10. Taskin MI, Bulbul E, Adali E, et al. Circulating levels
of obestatin and copeptin in obese and nonobese
women with polycystic ovary syndrome. European
Journal of Obstetrics & Gynecology and Reproductive
Biology 2015;189:19-23.
11. El-Fattah AIA, Elboghdady AA, Kamel MM, et al.
Obestatin and Copeptin Levels in Egyptian Polycystic
Ovary Patients and their Relation to Obesity, Insulin
Resistance and Cardiovascular Risk. Merit Res J Med
Med Sci 2016;4:451-7.
12. Rahmani E, Akbarzadeh S, Broomand A, et al. Serum
Levels of Angiopoietin-Like Protein 2 and Obestatin
in Iranian Women with Polycystic Ovary Syndrome
and Normal Body Mass Index. J of Clinical Med
2018;7:159.
13. Wu W, Fan X, Yu Y, et al. Alteration of ghrelin/obestatin
ratio in adolescence with polycystic ovarian syndrome.
Gynecol Endocrinol 2018;34:36-9.
14. Ozbay Y, Aydin S, Dagli AF, et al. Obestatin is present
in saliva: alterations in obestatin and ghrelin levels
of saliva and serum in ischemic heart disease. BMB
reports 2008;41:55-61.
15. Ferriman D, Gallwey J. Clinical assessment of body
hair growth in women. J Clin Endocrinol Metab
1961;21:1440-7.
16. Revised 2003 consensus on diagnostic criteria and
long-term health risks related to polycystic ovary
syndrome (PCOS). Hum Reprod 2004;19:41-7.
17. Matthews D, Hosker J, Rudenski A, et al. Homeostasis
model assessment: insulin resistance and β-cell
function from fasting plasma glucose and insulin
concentrations in man. Diabetologia 1985;28:412-9.
18. Varli B, Ozmen B, Erguder BI, et al. Anorexigenic
peptide (leptin, obestatin, nesfatin-1) levels and their
impact on IVF/ICSI outcome in patients with polycystic
ovary syndrome. Eur J Obstet Gynecol Reprod Biol
2019;234:75.
19. Pasquali R, Gambineri A. Polycystic ovary syndrome:
a multifaceted disease from adolescence to adult age.
Ann N Y Acad Sci 2006;1092:158-74.
20. Ollila M-M, West S, Keinänen-Kiukaanniemi S, et al.
Overweight and obese but not normal weight women
with PCOS are at increased risk of Type 2 diabetes
mellitus—a prospective, population-based cohort
study. Hum Reprod 2017;32:423-31.
21. Durmus U, Duran C, Ecirli S. Visceral adiposity
index levels in overweight and/or obese, and non-
obese patients with polycystic ovary syndrome and
its relationship with metabolic and inflammatory
parameters. J Endocrinol Invest 2017;40:487-97.
22. Vryonidou A, Papatheodorou A, Tavridou A, et al.
Association of hyperandrogenemic and metabolic
phenotype with carotid intima-media thickness in
young women with polycystic ovary syndrome. J Clin
Endocrinol Metab 2005;90:2740-6.
23. Pelanis R, Mellembakken JR, Sundström-Poromaa I, et
al. The prevalence of Type 2 diabetes is not increased
in normal-weight women with PCOS. Hum Reprod
2017;32:2279-86.
24. Egido EM, Hernández R, Marco J, et al. Effect of
obestatin on insulin, glucagon and somatostatin
secretion in the perfused rat pancreas. Regul Pept
2009;152:61-6.
25. Nogueiras R, Pfluger P, Tovar S, et al. Effects of
obestatin on energy balance and growth hormone
secretion in rodents. Endocrinology 2007;148:21-6.
26. Huda M, Durham B, Wong S, et al. Plasma obestatin
levels are lower in obese and post-gastrectomy
subjects, but do not change in response to a meal. Int
J Obes 2008;32:129.
27. Gao X-Y, Kuang H-Y, Liu X-M, et al. Decreased
obestatin in plasma in metabolically obese, normal-
weight men with normal glucose tolerance. Diabetes
Res Clin Pract 2008;79:e5-e6.
28. Gao X-Y, Kuang H-Y, Liu X-M, et al. Decreased gastric
body mucosa obestatin expression in overweight and
obese patients. Peptides 2010;31:291-6.
29. Gurriarán-Rodrıguez U, Al-Massadi O, Crujeiras AB, et
al. RAPID COMMUNICATION Preproghrelin expression
is a key target for insulin action on adipogenesis. J
Endocrinol 2011;210:1-7.
30. Kołodziejski PA, Pruszyńska-Oszmałek E, Strowski
MZ, et al. Long-term obestatin treatment of mice type
2 diabetes increases insulin sensitivity and improves liver function. Endocrine 2017;56:538-50.